Biotech Values

[DewDiligence]

Squalamine dosing and scheduling:

The comment in today’s webcast about an additional phase-2 study to test monthly retreatment was a surprise to me because monthly scheduling (after the initial weekly*4 loading dose) strikes me as undesirably frequent from the standpoint of convenience and cost/reimbursement. The Squalamine data in the completed phase ½ trial seemed good enough at 2 months and 4 months to justify a longer retreatment interval than one month.

However, the kind of phase-2 trial mentioned today is not the dose-finding trial that some posters here and on Yahoo have been calling for. To the contrary, my interpretation of Dr. Levitt’s presentation is that GENR is satisfied with the 25mg/m2 dose and further work on the dose (as opposed to the dosing schedule) may not be needed.

Comments?